Please assess the completion status of the following clinical trial:

Trial Title: Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female~2. Age 18 to 45 years old (inclusive)~3. Using an acceptable method of contraception (if female of childbearing potential).~4. Able and willing to provide informed consent for study participation.~Exclusion Criteria:~1. Current acute febrile illness.~2. Clinically significant cardiac, respiratory, or rheumatologic disease, in the opinion of the Investigator.~3. Pregnant or breast-feeding.~4. Laboratory evidence of infection with Hepatitis B/C or HIV.~5. History of chikungunya virus infection.~6. Travel to a World Health Organization-designated chikungunya-endemic region within 30 days prior to Day 1.~7. History of allergic reaction to any component of CHIKV-VLP vaccine, Diluent, or Alhydrogel®.~8. Inability to discontinue systemic immunomodulatory or immunosuppressive medications 30 days prior to Day 1.~9. Received or plans to receive any licensed vaccine from 30 days prior to Day 1 through Day 57.~10. Received or plans to receive an investigational agent from 30 days prior to Day 1 through the duration of study participation.~11. Any other condition that, in the opinion of the Investigator, creates an unacceptable risk to the subject.~12. Any other condition that, in the opinion of the Investigator, may interfere with the conduct of the study or the validity of the data.~13. Any other condition that, in the opinion of the Investigator, creates an unacceptable safety risk for apheresis (Group 9 \& 10 only).~14. Restricted venous access that would prevent the collection of PBMCs, plasma, and lymphocytes necessary for participation (Group 9 \& 10 only).~15. Weight \< 110 pounds (Group 9 \& 10 only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: 20 mcg/unadjuvanted (Day 1 & 29) (Type: EXPERIMENTAL): 20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)
- Group 2: 6 mcg/adjuvanted (Day 1 & 29) (Type: EXPERIMENTAL): 6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
- Group 3: 10 mcg/adjuvanted (Day 1 & 29) (Type: EXPERIMENTAL): 10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
- Group 4: 20mcg/adjuvanted (Day 1 & 29);40mcg/adjuvant (Day 547) (Type: EXPERIMENTAL): 20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)
- Group 5: 6 mcg/adjuvanted (Day 15 & 29) (Type: EXPERIMENTAL): Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
- Group 6: 10 mcg/adjuvanted (Day 15 & 29) (Type: EXPERIMENTAL): Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
- Group 7: 20 mcg/adjuvanted (Day 15 & 29) (Type: EXPERIMENTAL): Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
- Group 8: 40 mcg/adjuvanted (Day 29) (Type: EXPERIMENTAL): Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)
- Group 9: 20 mcg/adjuvanted (Day 1 & 29) (Type: EXPERIMENTAL): 20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182
- Group 10: 40 mcg/adjuvanted (Day 1) (Type: EXPERIMENTAL): 40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).